ArticleCureus2025
Lung Manifestations of Metastatic Duodenal Adenocarcinoma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary lymphangitic carcinomatosis (PLC) is a rare condition characterized by malignant infiltration within the lymphatic system. It most often arises from adenocarcinoma of the breast, lung, or pancreas. This rare diagnosis often evades detection due to diagnostic challenges, unknown pathogenesis, and indolent presentation. Villous adenoma of the duodenum is also an exceedingly rare malignancy that is often mistaken for various pancreatic pathologies. To our knowledge, we describe the first case of PLC secondary to biopsy-confirmed villous adenocarcinoma of the duodenum in a 56-year-old male who presented with dyspnea, cough, and weight loss. This case illustrates how an indolent-appearing duodenal lesion can manifest as aggressive pulmonary metastasis, emphasizing the need for clinicians to maintain a broad differential when evaluating diffuse pulmonary disease and the importance of integrating radiographic, histopathologic, molecular, and multidisciplinary tools to identify rare metastatic origins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.